John Samples
Ophthalmology · Olympia, WANPI 1598717860
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,991 of the $114,953 with a category attached, or 78.3%. 9 manufacturers reported payments, led by Novartis at 53.1% of the total. Reporting peaked in 2019 at $80,856 and has fallen 99.9% since, to $62 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $827.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$61K
- Aerie Pharmaceuticals, Inc.$48K
- Thea Pharma Inc.$4K
- AbbVie$631
- Bausch & Lomb, A Division Of Bausch Health US, LLC$468
- Bausch & Lomb Americas Inc.$226
- plus $446 from 3 others
What the payments were for
- Consulting fees$8,9258%
- Speaking & faculty fees$89,99178%
- Travel & lodging$11,42810%
- Food & beverage$4,4854%
- Gifts$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 68 | $61,058 |
| Aerie Pharmaceuticals, Inc. | 37 | $47,671 |
| Thea Pharma Inc. | 10 | $4,454 |
| AbbVie(2 entities) | 10 | $631 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $468 |
| Bausch & Lomb Americas Inc. | 4 | $226 |
| Alcon | 2 | $221 |
| Amgen | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,953 in reported general payments places this provider in the 95th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 89 | $44,518 |
| VyzultaLatanoprostene Bunod | 92 | $34,936 |
| Travoprost | 151 | $23,092 |
| IyuzehLatanoprost/Pf | 36 | $14,306 |
| Brinzolamide | 64 | $12,907 |
| LumiganBimatoprost | 15 | $9,275 |
| Alphagan PBrimonidine Tartrate | 24 | $8,453 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $6,355 |
| TafluprostTafluprost/Pf | 20 | $5,341 |
| Prednisolone Acetate | 66 | $3,015 |
| Timolol Maleate | 139 | $3,011 |
| Dorzolamide Hcl | 98 | $1,681 |
| Latanoprost | 133 | $1,545 |
| Brimonidine Tartrate | 33 | $1,217 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 81 | $1,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $47,671 | $50,873104 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $226 | $34,93692 claims |
| AbbVieLumigan, Alphagan P | $631 | $17,72839 claims |
| Thea Pharma Inc.Iyuzeh | $4,454 | $14,30636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Olympia
- Noel CastilloOlympia$5K
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.